Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2023 | 179 | 0.740 |
Why?
|
| Paraproteinemias | 1 | 2023 | 250 | 0.710 |
Why?
|
| Nephrology | 1 | 2023 | 263 | 0.690 |
Why?
|
| Calcitriol | 1 | 2018 | 295 | 0.550 |
Why?
|
| Kidney Diseases | 4 | 2023 | 2092 | 0.510 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 1923 | 0.470 |
Why?
|
| Biological Products | 1 | 2023 | 913 | 0.470 |
Why?
|
| Phosphates | 1 | 2016 | 763 | 0.400 |
Why?
|
| Kidney | 7 | 2023 | 7034 | 0.340 |
Why?
|
| Body Composition | 1 | 2018 | 2427 | 0.310 |
Why?
|
| Nephritis, Interstitial | 2 | 2021 | 155 | 0.310 |
Why?
|
| Kidney Failure, Chronic | 4 | 2016 | 2478 | 0.310 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 2254 | 0.270 |
Why?
|
| Primary Myelofibrosis | 2 | 2019 | 208 | 0.270 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2007 | 289 | 0.240 |
Why?
|
| Health Status | 1 | 2018 | 4077 | 0.240 |
Why?
|
| Renal Dialysis | 5 | 2021 | 1796 | 0.220 |
Why?
|
| Vasculitis | 1 | 2007 | 522 | 0.210 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2020 | 225 | 0.200 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 808 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 13630 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 2181 | 0.170 |
Why?
|
| Aging | 1 | 2018 | 8701 | 0.160 |
Why?
|
| Hemodialysis, Home | 1 | 2018 | 20 | 0.150 |
Why?
|
| Diet | 1 | 2016 | 8047 | 0.150 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 123 | 0.140 |
Why?
|
| Neoplasms | 2 | 2023 | 22125 | 0.140 |
Why?
|
| Proteinuria | 1 | 2019 | 604 | 0.130 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2018 | 335 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2019 | 549 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 4189 | 0.110 |
Why?
|
| Independent Living | 1 | 2018 | 579 | 0.110 |
Why?
|
| Heart Failure | 1 | 2018 | 11701 | 0.110 |
Why?
|
| Random Allocation | 1 | 2018 | 2393 | 0.110 |
Why?
|
| Premenopause | 2 | 2007 | 1038 | 0.110 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2007 | 369 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2007 | 4642 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 15513 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2019 | 1274 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 5478 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 2047 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2019 | 2010 | 0.080 |
Why?
|
| Evoked Potentials, Visual | 1 | 2010 | 417 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 3493 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2813 | 0.070 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 1288 | 0.070 |
Why?
|
| Mortality | 1 | 2018 | 2896 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 488 | 0.070 |
Why?
|
| Cytotoxins | 1 | 2007 | 153 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2018 | 2293 | 0.070 |
Why?
|
| Hepatic Insufficiency | 1 | 2005 | 14 | 0.060 |
Why?
|
| Angina Pectoris | 1 | 2009 | 959 | 0.060 |
Why?
|
| Cause of Death | 1 | 2016 | 3688 | 0.060 |
Why?
|
| Humans | 20 | 2023 | 761098 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2009 | 874 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 694 | 0.060 |
Why?
|
| Ferric Compounds | 1 | 2005 | 378 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2019 | 7969 | 0.050 |
Why?
|
| Insulin Resistance | 2 | 2007 | 3951 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 4308 | 0.050 |
Why?
|
| Melanoma | 1 | 2021 | 5694 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5662 | 0.050 |
Why?
|
| Steroids | 1 | 2007 | 929 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 14607 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 2219 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12467 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2007 | 961 | 0.050 |
Why?
|
| Middle Aged | 12 | 2020 | 220835 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2007 | 1893 | 0.040 |
Why?
|
| Male | 11 | 2020 | 360675 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2018 | 41486 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2007 | 1589 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2005 | 1027 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2019 | 385 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2007 | 1579 | 0.030 |
Why?
|
| Female | 11 | 2020 | 392458 | 0.030 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 333 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 2191 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39121 | 0.030 |
Why?
|
| Biopsy | 2 | 2019 | 6781 | 0.030 |
Why?
|
| Anemia | 1 | 2005 | 1504 | 0.030 |
Why?
|
| Insulin | 2 | 2007 | 6588 | 0.030 |
Why?
|
| Aged | 6 | 2020 | 169266 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2019 | 664 | 0.030 |
Why?
|
| Adult | 9 | 2020 | 221083 | 0.030 |
Why?
|
| Ferritins | 2 | 2007 | 597 | 0.030 |
Why?
|
| Retrospective Studies | 6 | 2021 | 80673 | 0.030 |
Why?
|
| Nitriles | 1 | 2019 | 971 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2010 | 12951 | 0.030 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2010 | 27 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 3725 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 9185 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 4822 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 10203 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2009 | 284 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 6817 | 0.020 |
Why?
|
| Incidence | 2 | 2021 | 21357 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2018 | 2329 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2019 | 3026 | 0.020 |
Why?
|
| Glucaric Acid | 1 | 2005 | 10 | 0.020 |
Why?
|
| Hematocrit | 1 | 2007 | 623 | 0.020 |
Why?
|
| C-Peptide | 1 | 2007 | 441 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12727 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2007 | 400 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 1376 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 602 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 64670 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2009 | 6343 | 0.010 |
Why?
|
| Iron | 1 | 2007 | 1790 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6482 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2007 | 2380 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 29672 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 23415 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2007 | 3309 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2009 | 9317 | 0.010 |
Why?
|
| Adolescent | 3 | 2007 | 88271 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 58946 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 18385 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 7513 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 22157 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 6504 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2007 | 54419 | 0.000 |
Why?
|
| Risk Factors | 1 | 2009 | 74219 | 0.000 |
Why?
|
Concepts
(123)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_